基本數據
| CIK | 1795251 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nano-X Imaging Ltd.
SEC Filings (Chronological Order)
本頁面提供了一個完整的、按時間順序排列的美國證券交易委員會（SEC）申報文件列表，不包括我們在其他地方提供的所有權申報。
| April 30, 2026 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Erez Meltzer, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 30, 2026 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-294302, 333-271688) and on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated April 30, 2026 relating to the financial statements and the effectiveness of internal control over financial reporting, which app |
|
| April 30, 2026 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| April 30, 2026 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ran Daniel, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| April 30, 2026 |
Exhibit 4.20 160 Robinson Road #21-09 SBF Center Singapore 068914 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[REDACTED]” indicates where the information has been omitted from this exhibit. VOLUME SUPPLY AGREEMENT This Volume Supply Agreement |
|
| April 30, 2026 |
DEVELOPMENT AND PURCHASE AGREEMENT Exhibit 4.19 Certain identified information contained in this document, marked by brackets, was omitted because it is both (i) not material and (ii) is the type that the Company treats as private or confidential. “[REDACTED]” indicates where the information has been omitted from this exhibit. DEVELOPMENT AND PURCHASE AGREEMENT This Development and Purchase agreement is executed and effective from |
|
| April 30, 2026 |
Exhibit 2.1 Description of Securities As of December 31, 2025, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares. References herein to “we,” “us,” “our” and the “Company” refer to NANO-X IMAGING LTD. and not to any of its subsidiaries. The following description may not contain all |
|
| April 30, 2026 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Erez Meltzer, Chief Executive Officer of th |
|
| April 20, 2026 |
Exhibit 99.1 Nanox Announces Fourth Quarter of 2025 Financial Results and provides Business Updates Advanced commercialization in the US, signing multiple new customer and distribution agreements for Nanox.ARC and accelerated activities around Nanox.AI Management to host conference call and webcast Monday, April 20, 2026 at 8:30 AM ET Appointed new CFO effective August 1, 2026 PETACH TIKVA, Israel |
|
| April 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2026 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mar |
|
| March 26, 2026 |
NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 March 26, 2026 VIA EDGAR U. |
|
| March 26, 2026 |
As filed with the Securities and Exchange Commission on March 26, 2026 As filed with the Securities and Exchange Commission on March 26, 2026 Registration No. |
|
| March 26, 2026 |
Exhibit 4.7 NANO-X IMAGING LTD INDENTURE Dated as of [ ] DEBT SECURITIES [ ] Trustee Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 § 311 11.01(f), 16.02 § 312 14.02(d), 16.02 (b) 11.10, 16.02 (c) 11.10, 16.02 § 313 (a) 10.01(a), 16.02 § |
|
| March 23, 2026 |
March 23, 2026 Erez Meltzer Chief Executive Officer Nano-X Imaging Ltd. Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 Re: Nano-X Imaging Ltd. Registration Statement on Form F-3 Filed March 13, 2026 File No. 333-294302 Dear Erez Meltzer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding |
|
| March 13, 2026 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 NANO-X IMAGING LTD Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, par value NIS 0. |
|
| March 13, 2026 |
Exhibit 2.6 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (“Agreement”) is made and entered into as of this 18 day of November, 2025 by and between VASOHEALTHCARE IT Corp., a Delaware (“Company”), Vaso Corporation, a Delaware corporation (“Seller”) and Nano – X Imaging Inc., a company organized under the laws of the State of Delaware (“Purchaser”). BACKGROUND Seller owns 100 shares of com |
|
| March 13, 2026 |
As filed with the Securities and Exchange Commission on March 13, 2026 As filed with the Securities and Exchange Commission on March 13, 2026 Registration No. |
|
| February 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| February 3, 2026 |
Exhibit 99.1 Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis scan, enabling both 3D and 2D views from a single sca |
|
| December 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| December 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 26, 2025 |
Exhibit 4.1 Execution Version Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 49th Floor New York, NY 10007 November 23, 2025 Nano-X Imaging Ltd. Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva, Israel 4970602 Attn: Erez Meltzer Re: Placement Agency Agreement Dear Mr. Meltzer Subject to the terms and conditions of this letter agreement (the “Agreem |
|
| November 26, 2025 |
Exhibit 4.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 23, 2025, between Nano-X Imaging Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the |
|
| November 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park Petach Tikva, Israel 4970602 (Address of principal executive office) Indicate by check mark whether the registr |
|
| November 25, 2025 |
NANO-X IMAGING LTD 3,826,530 Ordinary Shares Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-271688 PROSPECTUS SUPPLEMENT (To Prospectus dated May 8, 2024) NANO-X IMAGING LTD 3,826,530 Ordinary Shares We are issuing 3,826,530 ordinary shares, par value NIS 0.01 per share (the “ordinary shares”) in a registered direct offering to a single institutional investor (the “investor”) pursuant to this prospectus supplement and the ac |
|
| November 25, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES F-3 NANO-X IMAGING LTD Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees Previously Paid Equity Ordinary shares, par value NIS 0. |
|
| November 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park Petach Tikva, Israel 4970602 (Address of principal executive office) Indicate by check mark whether the registr |
|
| November 24, 2025 |
Nanox Announces $15 Million Registered Direct Offering of Common Stock Exhibit 99.1 Nanox Announces $15 Million Registered Direct Offering of Common Stock PETACH TIKVA, Israel, Nov. 23, 2025 — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“ |
|
| November 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 20, 2025 |
Exhibit 99.1 Nanox Announces Third Quarter of 2025 Financial Results and Provides Business Update Management to host conference call and webcast Thursday, November 20, 2025, at 8:30 AM ET Company advances commercialization and is on track to meet year-end system deployment target PETAH TIKVA, Israel— November 20, 2025 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative me |
|
| November 19, 2025 |
Exhibit 99.1 Nanox Reaches Agreement with Vaso Corporation to Acquire VasoHealthcare IT, Accelerating U.S. Rollout of AI Solutions PETACH TIKVA, Israel, Nov. 19, 2025 (GLOBE NEWSWIRE) - NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that the parties have agreed on the terms and conditions pursuant to which Nanox will a |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 17, 2025 |
NANO-X IMAGING LTD. (THE “COMPANY”) THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS Exhibit 99.2 NANO-X IMAGING LTD. (THE “COMPANY”) PROXY THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS I, the undersigned, shareholder of Nano-X Imaging Ltd. (the “Company”), hereby nominate, constitute and appoint each of Mr. Erez Meltzer, Chief Executive Officer of the Company and Ms. Marina Gofman Feler, Chief Legal Officer (GC), as my true and lawful proxy and attorney(s) with full power of |
|
| November 17, 2025 |
Exhibit 99.1 NANO-X IMAGING LTD The Ofer Tech Park, 94 Shlomo Shmeltzer Road Petach Tikva, Israel 4970602 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 22, 2025 Dear Shareholders: We cordially invite you to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd (“we” or the “Company”) to be held at the Company’s offices at The Ofer Tech Park, 94 Shlomo Shmeltzer |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check ma |
|
| August 12, 2025 |
Exhibit 99.1 Nanox Announces Second Quarter of 2025 Financial Results and Provides Business Update Management to host conference call and webcast Tuesday, August 12, 2025 at 8:30 AM ET Company continued to grow Nanox.ARC installed base and is on track to meet its year-end system deployment target PETAH TIKVA, Israel— August 12, 2025 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), a |
|
| May 22, 2025 |
Exhibit 99.1 Nanox Announces First Quarter 2025 Financial Results and Provides Business Updates Management to host conference call and webcast on Thursday, May 22, 2025 at 8:30 AM ET PETACH TIKVA, Israel — May 22, 2025 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced results for the first quarter ended March 31, 2025, |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mar |
|
| April 17, 2025 |
Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X Exhibit 99.1 Nanox Receives FDA Clearance for General Use of New Imaging System, Nanox.ARC X · First FDA clearance for Nanox.ARC X to produce tomographic images for general use, including musculoskeletal, pulmonary, intra-abdominal and paranasal indications · Enhanced imaging system features sleek design with smaller footprint; simplified ‘plug and play’ installation process · System design enable |
|
| April 9, 2025 |
Exhibit 2.1 Description of Securities As of December 31, 2024, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares. References herein to “we,” “us,” “our”and the “Company” refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain all of |
|
| April 9, 2025 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| April 9, 2025 |
Insider Trading Compliance Policy (2024) Exhibit 11.1 Insider Trading Compliance Policy (2024) Contents Page I. Summary 2 II. Statement of Policies Prohibiting Insider Trading 3 III. Explanation of Insider Trading 4 IV. Statement of Procedures to Prevent Insider Trading 7 V. Additional Prohibited Transactions 9 VI. Rule 10b5-1 Trading Plans 10 Insider Trading Compliance Policy U.S. federal securities laws prohibit trading in the securiti |
|
| April 9, 2025 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Erez Meltzer, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 9, 2025 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Erez Meltzer, Chief Executive Officer and A |
|
| April 9, 2025 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-271688) and on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated April 9, 2025 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this F |
|
| April 9, 2025 |
Exhibit 4.13 COMPENSATION POLICY NANO-X IMAGING LTD. Compensation Policy for Executive Officers and Directors (As Adopted on June 25, 2024) A. Overview and Objectives 1. Introduction This document sets forth the Compensation Policy for Executive Officers and Directors (this “Compensation Policy” or “Policy”) of NANO-X IMAGING LTD. (“NNOX” or the “Company”), in accordance with the requirements of t |
|
| April 9, 2025 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ran Daniel, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mar |
|
| March 31, 2025 |
Exhibit 99.1 Nanox Announces Fourth Quarter of 2024 Financial Results and provides Business Updates Recorded noted regulatory successes with FDA general use clearance and granting of CE Mark in the EU Advanced commercialization globally, signing new customer and channel partner agreements for Nanox.ARC and Nanox AI Management to host conference call and webcast Monday, March 31, 2025 at 8:30 AM ET |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| February 25, 2025 |
Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market Exhibit 99.1 Nanox.ARC Imaging System Receives CE Mark, Expanding Medical Imaging Offering in European Market ● CE Mark is the first major regulatory milestone for Nanox.ARC Imaging System in the European market; follows recent general use FDA clearance in the U.S. ● New clinical data supporting use of Nanox.ARC to be presented at European Congress of Radiology (ECR) 2025 ● Nanox.ARC is an FDA, CE |
|
| December 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| December 5, 2024 |
Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication Exhibit 99.1 Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication ● Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication for the musculoskeletal system ● Nanox.ARC uses high voltage powered digital X-ray tu |
|
| December 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 21, 2024 |
Exhibit 99.1 Nanox Announces Third Quarter of 2024 Financial Results and Provides Business Update Made progress deploying all components of the Nanox solution including Nanox.ARC and Nanox.AI Expanded US sales and support staff a key component of global strategic growth plan Management to host conference call and webcast Thursday, November 21, 2024 at 8:30 AM ET PETACH TIKVA, Israel — November 21, |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| November 8, 2024 |
NNOX / Nano-X Imaging Ltd. / BlackRock, Inc. Passive Investment il0011681371110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NANO-X IMAGING LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BLB2P06 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| October 29, 2024 |
Exhibit 99.1 NANO-X IMAGING LTD The Ofer Tech Park, 94 Shlomo Shmeltzer Road Petach Tikva, Israel 4970602 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 3, 2024 Dear Shareholders: We cordially invite you to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd (“we” or the “Company”) to be held at the Company’s offices at The Ofer Tech Park, 94 Shlomo Shmeltzer R |
|
| October 29, 2024 |
NANO-X IMAGING LTD. (THE “COMPANY”) THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS Exhibit 99.2 NANO-X IMAGING LTD. (THE “COMPANY”) PROXY THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS I, the undersigned, shareholder of Nano-X Imaging Ltd. (the “Company”), hereby nominate, constitute and appoint each of Mr. Erez Meltzer, Chief Executive Officer of the Company and Ms. Marina Gofman Feler, Chief Legal Officer (GC), as my true and lawful proxy and attorney(s) with full power of |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check m |
|
| October 24, 2024 |
NNOX / Nano-X Imaging Ltd. / BlackRock, Inc. Passive Investment il0011681371102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NANO-X IMAGING LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BLB2P06 - (SEDOL Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| September 23, 2024 |
Exhibit 99.1 Nanox Analyst Day 2024 and its subsidiaries Nanox Analyst Day 2024 Nanox Analyst Day 2024 Nanox Analyst Day 2024 Cantor Global Healthcare Conference Nanox Analyst Day 2024 Nanox Analyst Day 2024 • • • • • • Nanox Analyst Day 2024 Chest 30% Hand 29% Head 5% Pelvis 4% Leg 13% Abdomen 6% Spine 13% Nanox Analyst Day 2024 Sherri Donaldson, COO at DRI, Kansas Dr. Todd Goldman, Chiropractor |
|
| August 20, 2024 |
Exhibit 99.1 Nanox Announces Second Quarter of 2024 Financial Results and Provides Business Update Accelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA 510K Clearance for HealthCCSng V 2.0, upgraded version of its AI Cardiac Solution Management to host conf |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check ma |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| June 7, 2024 |
$100,000,000 NANO-X IMAGING LTD. Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-271688 PROSPECTUS SUPPLEMENT (To Prospectus dated May 8, 2024) $100,000,000 NANO-X IMAGING LTD. We have entered into a Controlled Equity OfferingSM Sales Agreement, dated as of June 7, 2024 (the “sales agreement”) with Cantor Fitzgerald & Co. and Mizuho Securities USA LLC (each individually, an “Agent” and collectively, the “Agents”) |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| June 7, 2024 |
NANO-X IMAGING LTD Ordinary Shares Controlled Equity OfferingSM Sales Agreement Exhibit 10.1 Execution Version NANO-X IMAGING LTD Ordinary Shares Controlled Equity OfferingSM Sales Agreement June 7, 2024 Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, NY 10022 Mizuho Securities USA LLC 1271 Avenue of the Americas, 3rd Floor New York, NY 10020 Ladies and Gentlemen: NANO-X IMAGING LTD, a company organized under the laws of the State of Israel (the “Company”), |
|
| June 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Amended and Restated Articles of Association) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid — — — — — — — — — — — — — — — Fees Previously Paid Equity — Ordinary shares, par value NIS 0. |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| May 28, 2024 |
Exhibit 99.1 Nanox Announces First Quarter of 2024 Financial Results and Provides Business Update Accelerates Deployment of Nanox.ARC in United States signed two commercial agreements for Nanox.AI Management to host conference call and webcast Tuesday, May 28, 2024 at 8:30 AM ET PETAH TIKVA, Israel— May 28, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical |
|
| May 8, 2024 |
Notice of Special General Meeting of Shareholders To be Held on June 18, 2024 Exhibit 99.1 May 8, 2024 Dear Nano-X Imaging Ltd. Shareholders: We cordially invite you to attend the Special General Meeting of Shareholders of Nano-X Imaging Ltd. (the “Meeting”), to be held on June 18, 2024 at 15:00 (Israel time), at the offices of the Company located at Ofer Tech Park, 94 Shlomo Shmeltzer Road Petach Tikva 4970602, Israel. At the Meeting, shareholders will be asked to consider |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mark |
|
| May 8, 2024 |
NANO-X IMAGING LTD. (THE “COMPANY”) THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS Exhibit 99.2 NANO-X IMAGING LTD. (THE “COMPANY”) PROXY THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS I, the undersigned, shareholder of Nano-X Imaging Ltd. (the “Company”), hereby nominate, constitute and appoint each of Mr. Erez Meltzer, Chief Executive Officer of the Company and Ms. Marina Gofman Feler, Chief Legal Officer (GC), as my true and lawful proxy and attorney(s) with full power of |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables POST-EFFECTIVE AMENDMENT TO FORM F-3ASR (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Offering Fees to be Paid Equity Ordinary shares, par value NIS 0. |
|
| April 22, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| April 22, 2024 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Erez Meltzer, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| April 22, 2024 |
As filed with the Securities and Exchange Commission on April 22, 2024 As filed with the Securities and Exchange Commission on April 22, 2024 Registration No. |
|
| April 22, 2024 |
Exhibit 2.1 Description of Securities As of December 31, 2023, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares. References herein to “we,” “us,” “our” and the “Company” refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain all o |
|
| April 22, 2024 |
As filed with the Securities and Exchange Commission on April 22, 2024 As filed with the Securities and Exchange Commission on April 22, 2024 Registration No. |
|
| April 22, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-271688) and on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated April 22, 2024 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this |
|
| April 22, 2024 |
Nanox Files 2023 Annual Report on Form 20-F Exhibit 99.1 Nanox Files 2023 Annual Report on Form 20-F PETACH TIKVA, Israel-(BUSINESS WIRE)—April 22, 2024- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, |
|
| April 22, 2024 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ran Daniel, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 22, 2024 |
NANO-X IMAGING LTD. RECOUPMENT POLICY Exhibit 97.1 NANO-X IMAGING LTD. RECOUPMENT POLICY The Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of Nano-X Imaging Ltd. (the “Company”) believes that it is appropriate for the Company to adopt this Recoupment Policy (the “Policy”) to be applied to the Executive Officers of the Company and adopts this Policy to be effective as of the Effective Date. This Polic |
|
| April 22, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mar |
|
| April 22, 2024 |
Exhibit 4.8 NANO-X IMAGING LTD INDENTURE Dated as of [ ] DEBT SECURITIES [ ] Trustee Reconciliation and tie between Trust Indenture Act of 1939 and Indenture* Trust Indenture Act Section Indenture Section § 310 (a) 11.04(a), 16.02 (b) 11.01(f), 11.04(b), 11.05(1), 16.02 (b)(1) 11.04(b), 16.02 § 311 11.01(f), 16.02 § 312 14.02(d), 16.02 (b) 11.10, 16.02 (c) 11.10, 16.02 § 313 (a) 10.01(a), 16.02 § |
|
| April 1, 2024 |
Exhibit 99.1 Nanox Announces Fourth Quarter of 2023 Financial Results and Provides Business Update Nanox Launches Nanox.ARC in United States with Installations Across Five States, Marking a Major Advancement in Medical Imaging Management to host conference call and webcast Monday, April 1, 2024 at 8:30 AM ET PETAH TIKVA, Israel— April 1, 2024 — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Co |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check mar |
|
| March 7, 2024 |
NNOX / Nano-X Imaging Ltd. / BlackRock Inc. Passive Investment il0011681371030624.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) NANO-X IMAGING LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BLB2P06 - (SEDOL Number) February 29, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check |
|
| February 13, 2024 |
Exhibit 99.1 Nanox Receives FDA Clearance for HealthFLD, an Advanced AI-Based Software Empowering Clinicians in Assessment of Fatty Liver Nanox’s HealthFLD is pioneering the use of a fully automated AI software for liver attenuation analysis from CT scans that has received FDA 510(k) clearance for use in general population Expands Nanox’s offering in AI solutions, marking third product in Nanox AI |
|
| February 6, 2024 |
NNOX / Nano-X Imaging Ltd. / BlackRock Inc. Passive Investment il0011681371020524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) NANO-X IMAGING LTD - (Name of Issuer) Common Stock - (Title of Class of Securities) BLB2P06 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check m |
|
| January 16, 2024 |
Nanox Mourns Death of Its Founder, Ran Poliakine Exhibit 99.1 Nanox Mourns Death of Its Founder, Ran Poliakine PETACH TIKVA, Israel, Jan. 16, 2024 (GLOBE NEWSWIRE) – NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced that the Company’s founder and non-executive chairman, Ran Poliakine, passed away on Friday, Jan. 12, 2024, due to a medical condition. Mr. Poliakine was a seria |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check m |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check m |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39461 NANO-X IMAGING LTD Ofer Tech Park 94 Shlomo Shmeltzer Road Petach Tikva Israel 4970602 (Address of principal executive office) Indicate by check m |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| December 4, 2023 |
Exhibit 99.1 |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 28, 2023 |
Exhibit 99.1 Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million Management to host conference call and webcast Tuesday, November 28, 2023 at 8:30 AM ET Management |
|
| November 16, 2023 |
Exhibit 99.1 NANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 27, 2023 Dear Shareholders: We cordially invite you to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd (“we” or the “Company”) to be held at the Company’s offices at The Communications Center, Neve Ilan, Israel on Wednesday, Dec |
|
| November 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 16, 2023 |
Exhibit 99.2 |
|
| October 3, 2023 |
Exhibit 99.1 Nanox Announces Strategic Manufacturing Agreement with Varex Imaging Corporation to Advance the Nanox.ARC Medical Imaging System NEVE ILAN, Israel and SALT LAKE CITY – October 3, 2023, (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company today announced the entrance into a manufacture and supply agreement with Varex Imaging Corporation (“Varex,” N |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regi |
|
| August 17, 2023 |
Exhibit 99.1 Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $80.3 million Management to host conference call and webcast Thursday, August 17, 2023 at 8:30 AM ET NEVE ILAN, Israel— August 17, 2023 - |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regis |
|
| July 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM 424(b)(5) (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Primary Offering Fees to be Paid Equity Ordinary shares, par value NIS 0. |
|
| July 26, 2023 |
Exhibit 4.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 23, 2023, between Nano-X Imaging Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the term |
|
| July 26, 2023 |
WARRANT TO PURCHASE ORDINARY SHARES Nano-X Imaging Ltd. Exhibit 4.3 WARRANT TO PURCHASE ORDINARY SHARES Nano-X Imaging Ltd. Warrant Shares: Original Issuance Date: July [*], 2023 Initial Exercise Date: July [*], 2023 THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| July 26, 2023 |
A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Exhibit 4.1 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 July 23, 2023 Nano-X Imaging Ltd. Communications Center Neve Ilan, Israel 9085000 Attn: Erez Meltzer Re: Placement Agency Agreement Dear Mr. Meltzer Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.” |
|
| July 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark |
|
| July 26, 2023 |
As filed with the Securities and Exchange Commission on July 26, 2023 As filed with the Securities and Exchange Commission on July 26, 2023 Registration No. |
|
| July 26, 2023 |
Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-271688 PROSPECTUS SUPPLEMENT (To Prospectus dated May 5, 2023) NANO-X IMAGING LTD 2,142,858 Ordinary Shares Warrants to Purchase 2,142,858 Ordinary Shares 2,142,858 Ordinary Shares Issuable Upon Exercise of Warrants We are issuing 2,142,858 ordinary shares, par value NIS 0.01 per share (the “ordinary shares”), and warrants to purchase |
|
| July 26, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3ASR (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Primary Offering Fees to be Paid Equity Ordinary shares, par value NIS 0. |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark |
|
| July 24, 2023 |
NANOX ANNOUNCES $30 MILLION REGISTERED DIRECT OFFERING Exhibit 99.1 NANOX ANNOUNCES $30 MILLION REGISTERED DIRECT OFFERING NEVE ILAN, Israel, July 24, 2023 (GLOBE NEWSWIRE) - NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with certain institutional investors for the purchase and sale of 2,142,857 of the Company’s ord |
|
| May 22, 2023 |
Exhibit 99.1 Nanox Announces First Quarter of 2023 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the first quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $91.0 million Management to host conference call and webcast Monday, May 22, 2023 at 8:30 AM ET NEVE ILAN, Israel— May 22, 2023 - NANO-X IM |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| May 5, 2023 |
As filed with the Securities and Exchange Commission on May 5, 2023 As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| May 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Primary Offering Fees to be Paid Equity Ordinary shares, par value NIS 0. |
|
| May 5, 2023 |
RW 1 ea178060-rwnanoximaging.htm WITHDRAWAL REQUEST May 5, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E Washington, D.C. 20549 United States of America RE: NANO-X IMAGING LTD Request to Withdraw Registration Statement on Form F-3 (File No. 333-271593) Ladies and Gentlemen: Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), NANO-X IMAGIN |
|
| May 3, 2023 |
As filed with the Securities and Exchange Commission on May 3, 2023 As filed with the Securities and Exchange Commission on May 3, 2023 Registration No. |
|
| May 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Primary Offering Fees to be Paid Equity Ordinary shares, par value NIS 0. |
|
| May 1, 2023 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.1 Description of Securities As of December 31, 2022, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our ordinary shares. References herein to “we,” “us,” “our” and the “Company” refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain all o |
|
| May 1, 2023 |
Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging Exhibit 99.1 Nanox.ARC Imaging System Receives FDA Clearance, Pioneering a New Era in Medical Imaging - Nanox.ARC presents high powered digital X-ray tubes for 3D tomosynthesis imaging - Nanox.ARC could help expand the availability of medical imaging NEVE ILAN, Israel, May 1, 2023 (GLOBE NEWSWIRE) – NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technolo |
|
| May 1, 2023 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated May 1, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. Tel-Aviv, Israel /s/ Kesse |
|
| May 1, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 1, 2023 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ran Daniel, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| May 1, 2023 |
Nanox Files 2022 Annual Report on Form 20-F Exhibit 99.1 Nanox Files 2022 Annual Report on Form 20-F NEVE ILAN, Israel-(BUSINESS WIRE)—May 1, 2023- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 with the U.S. Securities and Exchange Commission (“SEC”) on May 1, 2023. The |
|
| May 1, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-X Imaging Ltd. (the “Company”) for the twelve-months ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Ran Daniel, Chief Financial Officer of the |
|
| May 1, 2023 |
Exhibit 4.15 FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT THIS FIRST AMENDMENT TO STOCK PURCHASE AGREEMENT (this “Amendment”) is made and entered as of April 28, 2023, by and among Dr. Michael Yuz as the Seller Representative, NANO-X IMAGING, INC., a Delaware corporation (the “Buyer”), and NANO-X IMAGING LTD., a company organized under the laws of the state of Israel (the “Parent”). RECITALS WHEREA |
|
| May 1, 2023 |
Exhibit 4.14 SETTLEMENT AGREEMENT AND RELEASE This Settlement Agreement and Release (the “Agreement”) summarizes the terms for the settlement by and among Nano-X Imaging Ltd (“Nanox”), and Nano-X AI Ltd. (formerly Zebra Medical Vision Ltd.) (the “Company”), and Perryllion Ltd. (the “Equityholders Representative”), solely in its capacity as the representative of all Equityholders, as of the 29 Dece |
|
| May 1, 2023 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Erez Meltzer, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| March 9, 2023 |
United States securities and exchange commission logo March 9, 2023 Ran Daniel Chief Financial Officer Nano-X Imaging Ltd. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regist |
|
| March 9, 2023 |
EX-99.1 2 ea170252ex99-1nanox.htm PRESS RELEASE, DATED MARCH 9, 2023 Exhibit 99.1 Nanox Announces Fourth Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the fourth quarter of 2022 with cash, cash equivalents and marketable securities of $102.9 million Management to host conference call and webcast Thursday, March 9, 2023 at |
|
| March 2, 2023 |
March 2, 2023 BY E-MAIL AND BY EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F St. |
|
| February 23, 2023 |
Nanox to Report Fourth Quarter 2022 Financial Results on March 9, 2023 Exhibit 99.1 Nanox to Report Fourth Quarter 2022 Financial Results on March 9, 2023 NEVE ILAN, Israel, Feb 23, 2023 (GLOBE NEWSWIRE) - NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX) will report its financial results for the fourth quarter ended December 31, 2022 before market on Thursday, March 9, 2023. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, wi |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| February 14, 2023 |
Exhibit 99.1 Nanox.AI Connects to Nuance Precision Imaging Network to Improve Early Detection of Chronic Diseases with Workflow-Integrated AI The secure nationwide AI-powered cloud platform streamlines care team communication and delivers patient-specific imaging insights within clinical workflows NEVE ILAN, Israel, February 14, 2023 – NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), a |
|
| February 14, 2023 |
NNOX / Nano-X Imaging Ltd / Poliakine Ran - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* NANO-X IMAGING LTD (Name of Issuer) ORDINARY SHARES (Title and Class of Securities) M70700105 (CUSIP Number) DECEMBER 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| February 3, 2023 |
United States securities and exchange commission logo February 3, 2023 Ran Daniel Chief Financial Officer Nano-X Imaging Ltd. |
|
| February 1, 2023 |
CORRESP 1 filename1.htm February 1, 2023 BY E-MAIL AND BY EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F St., N.E. Washington, D.C. 20549 Attn: Tracey Houser Terence O’Brien Re: Nano-X Imaging Ltd. Form 20-F for Fiscal Year Ended December 31, 2021 Filed May 2, 2022 Response Letter Dated January 5, 2023 File No. 001-3946 |
|
| January 18, 2023 |
United States securities and exchange commission logo January 18, 2023 Ran Daniel Chief Financial Officer Nano-X Imaging Ltd. |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regi |
|
| January 5, 2023 |
CORRESP 1 filename1.htm January 5, 2023 BY E-MAIL AND BY EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F St., N.E. Washington, D.C. 20549 Attn: Tracey Houser Terence O’Brien Re: Nano-X Imaging Ltd. Form 20-F for Fiscal Year Ended December 31, 2021 Filed May 2, 2022 Form 6-K Filed March 31, 2022 File No. 001-39461 Dear Ms |
|
| December 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| December 6, 2022 |
United States securities and exchange commission logo December 6, 2022 Ran Daniel Chief Financial Officer Nano-X Imaging Ltd. |
|
| November 10, 2022 |
Exhibit 99.2 |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 10, 2022 |
Exhibit 99.1 Nanox Announces Third Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the third quarter of 2022 with cash, cash equivalents and marketable securities of $117.1 million Management to host conference call and webcast Thursday, November 10, 2022 at 8:30 AM ET NEVE ILAN, Israel— November 10, 2022 - NANO-X IMAGING L |
|
| November 10, 2022 |
Exhibit 99.1 NANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on December 21, 2022 Dear Shareholders: We cordially invite you to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd (“we” or the “Company”) to be held at the Company’s offices at The Communications Center, Neve Ilan, Israel on Wednesday, Dec |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the re |
|
| August 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regis |
|
| August 16, 2022 |
Exhibit 99.1 Nanox Announces Second Quarter 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the second quarter of 2022 with cash, cash equivalents and marketable securities of $126.7 million Management to host conference call and webcast today, August 16, 2022 at 8:30 AM ET NEVE ILAN, Israel?August 16, 2022 - NANO-X IMAGING LTD (NA |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| May 23, 2022 |
Exhibit 99.1 Nanox Announces its First Quarter of 2022 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the first quarter of 2022 with cash and marketable securities of $139.5 million Management to host conference call and webcast today, May 19, 2022 at 8:30 AM ET NEVE ILAN, Israel?May 19, 2022 - NANO-X IMAGING LTD (NASDAQ: NNOX) (?Nanox |
|
| May 2, 2022 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated May 2, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 20-F. Tel-Aviv, Israel /s/Kessel |
|
| May 2, 2022 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.1 Description of Securities As of December 31, 2021, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our ordinary shares. References herein to ?we,? ?us,? ?our? and the ?Company? refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain all o |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 2, 2022 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-x Imaging Ltd. (the ?Company?) for the twelve-months ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), Ran Daniel, Chief Financial Officer of the |
|
| May 2, 2022 |
Exhibit 4.4 Execution Version STOCK PURCHASE AGREEMENT by and among USARAD HOLDINGS, INC., dr. michael yuz, THE OTHER SELLERS LISTED ON THE SIGNATURE PAGE, Seller Representative, and NANO-X IMAGING, INC. and Nano-X Imaging Ltd. Dated as of October 25, 2021 TABLE OF CONTENTS Page 1. Definitions 2 1.1. Certain Matters of Construction 2 1.2. Certain Definitions 2 2. The Transaction 18 2.1. Purchase a |
|
| May 2, 2022 |
Exhibit 4.3 AMENDMENT NO. 1 TO THE AGREEMENT AND PLAN OF MERGER This Amendment No. 1 to the Agreement and Plan of Merger (the ?Amendment?) is entered into on October , 2021 by and among Nano-X Imaging Ltd, New Zealand Merger Sub Ltd., Nano-X Ai Ltd. (formerly Zebra Medical Vision Ltd.), and PerryLLion Ltd., solely in its capacity as the representative of all Equityholders. WHEREAS, the parties her |
|
| May 2, 2022 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with this Annual Report on Form 20-F of Nano-x Imaging Ltd. (the ?Company?) for the twelve-months ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), Ran Daniel, Chief Financial Officer of the |
|
| May 2, 2022 |
Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ran Daniel, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-x Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary |
|
| May 2, 2022 |
Exhibit 12.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Erez Meltzer, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-x Imaging Ltd.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| May 2, 2022 |
Exhibit 4.1 Execution Version ASSET PURCHASE AGREEMENT by and among MDWEB, LLC (doing business as MDW, LLC) and Nano-X Imaging, INC. and Nano-X Imaging Ltd. Dated as of October 21, 2021 TABLE OF CONTENTS Page 1. Definitions. 1 1.1. Certain Matters of Construction 1 1.2. Certain Definitions 2 2. The Transaction 12 2.1. Purchase and Sale of the Assets 12 2.2. Excluded Assets 12 2.3. Purchase Price 1 |
|
| May 2, 2022 |
Exhibit 4.2 AGREEMENT AND PLAN OF MERGER DATED AS OF AUGUST 9, 2021 BY AND AMONG NANO-X IMAGING LTD ZEBRA MEDICAL VISION LTD., NEW ZEALAND MERGER SUB LTD, AND PERRYLLION LTD Table of Contents Article I DEFINITIONS AND RULES OF CONSTRUCTION 3 Section 1.1 Defined Terms 3 Section 1.2 Certain References 3 Section 1.3 Rules of Construction 3 Article II THE MERGER 4 Section 2.1 Reverse Subsidiary Merger |
|
| April 5, 2022 |
Exhibit 99.1 Nanox Opens South Korean Fabrication Plant to Produce Semiconductor Chips for Novel Digital Nanox.ARC 3D X-ray System Fully operational facility will produce Nanox.SOURCE chip, the core innovative component of Nanox.ARC, which has potential to bring X-ray technology to two-thirds of the world without meaningful access Ramp up in production and preparation for shipments of the Nanox.AR |
|
| April 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regist |
|
| March 31, 2022 |
Exhibit 99.1 Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update Management to host conference call and webcast today, March 31, at 8:30 AM ET NEVE ILAN, Israel?March 31, 2022 - NANO-X IMAGING LTD (NASDAQ: NNOX) (?Nanox? or the ?Company?), an innovative medical imaging technology company, today announced results for the fourth quarter ended December 31, 2021 and prov |
|
| March 31, 2022 |
6-K 1 ea156793-6knanoximaging.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of pr |
|
| February 14, 2022 |
NNOX / Nano-X Imaging Ltd / SK TELECOM CO LTD - SCHEDULE 13G AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nano-X Imaging Ltd. (Name of Issuer) Ordinary shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check appropriate box to designate the rule pursuant to which this Sche |
|
| February 14, 2022 |
NNOX / Nano-X Imaging Ltd / Poliakine Ran - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* NANO-X IMAGING LTD (Name of Issuer) ORDINARY SHARES (Title and Class of Securities) M70700105 (CUSIP Number) DECEMBER 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 14, 2022 |
NNOX / Nano-X Imaging Ltd / SK square Co Ltd - SCHEDULE 13G Passive Investment SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nano-X Imaging Ltd. (Name of Issuer) Ordinary shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check appropriate box to designate the rule pursuant to whi |
|
| February 14, 2022 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with the other Reporting Person (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ord |
|
| February 14, 2022 |
NNOX / Nano-X Imaging Ltd / STONE RICHARD B Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nano-X Imaging Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regi |
|
| December 21, 2021 |
NNOX / Nano-X Imaging Ltd / Moalem Moshe - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nano-X Imaging Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M70700105 (CUSIP Number) November 22, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 7, 2021 |
6-K 1 ea151758-6knanoximaging.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 17, 2021 |
Exhibit 99.1 Nanox Announces Third Quarter 2021 Financial Results and Provides Business Update Reports progress towards global supply chain development Ended the third quarter with cash and marketable securities of $180.3 million Management to host conference call and webcast today, November 17, at 8:30 AM ET NEVE ILAN, Israel?November 17, 2021 - NANO-X IMAGING LTD (NASDAQ: NNOX) (?Nanox? or the ? |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regi |
|
| September 30, 2021 |
Exhibit 99.2 |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the re |
|
| September 30, 2021 |
Exhibit 99.1 NANO-X IMAGING LTD The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 5360360 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To Be Held on November 4, 2021 To our Shareholders: You are invited to attend the Annual Meeting of Shareholders of Nano-X Imaging Ltd (?we? or the ?Company?) to be held at the Company?s offices at The Communications Center, Neve Ilan, Israel |
|
| August 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regis |
|
| August 10, 2021 |
Exhibit 99.2 Nanox Announces Second Quarter 2021 Results and Provides Business Update Announces entry into acquisition via merger agreement with Zebra Medical Vision LTD. and binding letter of intent with USARAD Holdings Inc. to create a globally connected end-to-end radiology solution and population health platform Chairman and Chief Executive Officer, Ran Poliakine, will continue his role as Exe |
|
| August 10, 2021 |
Exhibit 99.1 Nanox Enters into Acquisition via Merger Agreement with Zebra Medical Vision Ltd. and Announces Entry into Binding Letter of Intent with USARAD Holdings Inc. with the Goal of Creating an Integrated, Globally Connected End-to-End Radiology Solution and Population Preventive Health Platform Upon the consummation of the acquisition, Nanox and Zebra Medical Vision anticipate that their mu |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regis |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registr |
|
| July 12, 2021 |
Exhibit 99.1 Nanox Signs MSaaS Agreement for the Deployment of 1,000 Nanox Systems in Nigeria Making its first steps in West Africa, Nanox partners with EiLEENO Pharma to make medical imaging accessible and available across Nigeria to both public and private medical institutions Neve Ilan, Israel & Kaduna state of Nigeria - July 12, 2021 ? NANO-X IMAGING LTD (?Nanox? or the ?Company,? Nasdaq: NNOX |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registr |
|
| June 17, 2021 |
Exhibit 99.1 Nanox Announces FDA 510(k) Submission for First Version of Multi-Source Nanox.ARC 510(K) Class II FDA submission seeks clearance of the first version of company’s multi-source 3-D digital tomosynthesis system as the next step in its U.S. regulatory process NEVE ILAN, Israel – June 17, 2021 - NANOX IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging tec |
|
| May 11, 2021 |
Exhibit 99.1 Nanox Announces First Quarter 2021 Results and Provides Business Update Announced FDA 510(k) clearance for the single source Nanox Cart X-Ray System Scaling up Company’s semiconductor fabrication plant in South Korea Ended Q1 with cash and cash equivalents of $219 million and no debt Management to host conference call and webcast today, May 11, at 8:30 AM ET NEVE ILAN, Israel—May 11, |
|
| May 11, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the registra |
|
| April 6, 2021 |
Description of Securities Registered under Section 12 of the Exchange Act Exhibit 2.2 Description of securities As of December 31, 2020, NANO-X IMAGING LTD had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): our ordinary shares. References herein to ?we,? ?us,? ?our? and the ?Company? refer to NANO-X IMAGING LTX and not to any of its subsidiaries. The following description may not contain all o |
|
| April 6, 2021 |
Exhibit 13.1 Certification by Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Ran Poliakine, Chief Executive Officer of Nano-X Imaging Ltd (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ● the Company’s annual report on Form 20-F for |
|
| April 6, 2021 |
Exhibit 15.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-248322) of Nano-X Imaging Ltd. of our report dated April 6, 2021 relating to the financial statements, which appears in this Form 20-F. Tel-Aviv, Israel /s/Kesselman & Kesselman April 6, 2021 Certified Public Accountants (Isr.) |
|
| April 6, 2021 |
Exhibit 13.2 Certification by Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Itzhak Maayan, Chief Financial Officer of Nano-X Imaging Ltd (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: ● the Company’s annual report on Form 20-F for |
|
| April 6, 2021 |
Exhibit 12.2 Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Itzhak Maayan, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 6, 2021 |
Exhibit 12.1 Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Ran Poliakine, certify that: 1. I have reviewed this annual report on Form 20-F of Nano-X Imaging Ltd (the ?Company?); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 2, 2021 |
Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray Exhibit 99.1 Nanox Announces FDA Clearance of 510(k) for Single Source Nanox.ARC Digital X-Ray NEVE ILAN, Israel – April 2, 2021 - NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration (the “FDA”). |
|
| April 2, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regist |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nano-X Imaging Ltd. (Name of Issuer) Ordinary shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| March 2, 2021 |
Exhibit 99.1 Nanox Announces Fourth Quarter 2020 Results and Provides Business Update Successfully demonstrates the Nanox.ARC in range of 2D and 3D imaging applications at the 2020 Radiology Society of North America (RSNA) Virtual Annual Meeting Continues to build out commercial and manufacturing infrastructure ahead of initial product shipments expected to commence in Q4 2021 and into Q1 2022 End |
|
| March 2, 2021 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the regist |
|
| February 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nano-X Imaging Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 16, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 NANO-X IMAGING LTD (Name of Issuer) ORDINARY SHARES (Title and Class of Securities) M70700105 (CUSIP Number) DECEMBER 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nano-X Imaging Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 12, 2021 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-252860 PROSPECTUS NANO-X IMAGING LTD ? 3,091,635 ORDINARY SHARES The selling shareholders named in this prospectus are offering 3,091,635 ordinary shares of NANO-X IMAGING LTD. We will not receive any proceeds from the sale of the shares being sold by the selling shareholders. Our ordinary shares are listed on The Nasdaq Globa |
|
| February 11, 2021 |
SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nano-X Imaging Ltd. (Name of Issuer) Ordinary shares (Title of Class of Securities) M70700105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check appropriate box to designate the rule pursuant to whi |
|
| February 11, 2021 |
EX-99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with the other Reporting Person (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ord |
|
| February 10, 2021 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on February 10, 2021. Registration No. 333-252860 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) State of Israel 3844 Not Applicable (State o |
|
| February 9, 2021 |
Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| February 8, 2021 |
February 8, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F St. |
|
| February 8, 2021 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on February 8, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NANO-X IMAGING LTD (Exact Name of Registrant as Specified in its Charter) State of Israel 3844 Not Applicable (State or Other Jurisdiction o |
|
| February 8, 2021 |
February 8, 2021 VIA EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission 100 F St. |
|
| February 8, 2021 |
List of subsidiaries of the Registrant EX-21.1 4 nt10018955x3ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Nanox Imaging, Inc. Japan Nano-X Korean Inc. Korea |
|
| February 8, 2021 |
NANO-X IMAGING LTD Ordinary Shares Underwriting Agreement Exhibit 1.1 NANO-X IMAGING LTD Ordinary Shares Underwriting Agreement [ ● ], 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule 1 hereto c/o Cantor Fitzgerald & Co. 110 East 59th Street, 4th Floor New York, NY 10022 Ladies and Gentlemen: Certain shareholders named in Schedule 2 hereto (the “Selling Shareholders”) of NANO-X IMAGING LTD, a company organized |
|
| February 1, 2021 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2021 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| January 21, 2021 |
United States securities and exchange commission logo January 21, 2021 Ran Poliakine Chief Executive Officer Nano-X Imaging Ltd. |
|
| January 21, 2021 |
United States securities and exchange commission logo January 21, 2021 Ran Poliakine Chief Executive Officer Nano-X Imaging Ltd. |
|
| January 19, 2021 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on January 19, 2021. |
|
| December 31, 2020 |
Current Report of Foreign Issuer - 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2020 Commission File Number: 001-39461 NANO-X IMAGING LTD Communications Center Neve Ilan, Israel 9085000 (Address of principal executive office) Indicate by check mark whether the reg |
|
| December 31, 2020 |
Exhibit 99.1 Nano-X Imaging Ltd The Communications Center Neve Ilan, Israel 9085000 Telephone: 972 2 536 0360 NOTICE OF SPECIAL GENERAL MEETING OF SHAREHOLDERS To Be Held on February 9, 2021 To our Shareholders: You are invited to attend a Special Meeting of Shareholders of Nano-X Imaging Ltd (“we” or the “Company”) to be held at the Company’s offices at The Communications Center, Neve Ilan, Israe |
